Vanguard Personalized Indexing Management LLC Acquires 26,573 Shares of Genmab A/S Sponsored ADR $GMAB

Vanguard Personalized Indexing Management LLC boosted its holdings in Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 50.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 79,257 shares of the company’s stock after buying an additional 26,573 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Genmab A/S were worth $2,431,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of GMAB. Osaic Holdings Inc. increased its position in Genmab A/S by 37.8% during the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after acquiring an additional 440 shares during the period. CWM LLC boosted its holdings in Genmab A/S by 50.5% in the 2nd quarter. CWM LLC now owns 1,797 shares of the company’s stock valued at $37,000 after purchasing an additional 603 shares during the period. AlphaCore Capital LLC acquired a new stake in Genmab A/S in the 2nd quarter worth $44,000. EverSource Wealth Advisors LLC increased its holdings in shares of Genmab A/S by 124.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company’s stock worth $44,000 after purchasing an additional 1,174 shares during the period. Finally, Cromwell Holdings LLC increased its holdings in shares of Genmab A/S by 136.3% during the 3rd quarter. Cromwell Holdings LLC now owns 1,531 shares of the company’s stock worth $47,000 after purchasing an additional 883 shares during the period. 7.07% of the stock is owned by institutional investors.

Genmab A/S Trading Up 1.3%

Shares of GMAB opened at $33.35 on Friday. The stock has a market cap of $21.42 billion, a PE ratio of 14.19, a PEG ratio of 18.54 and a beta of 0.90. Genmab A/S Sponsored ADR has a 1 year low of $17.24 and a 1 year high of $35.43. The stock has a 50 day simple moving average of $32.42 and a 200-day simple moving average of $28.97.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.65 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.17. Genmab A/S had a return on equity of 23.98% and a net margin of 41.36%.The firm had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $975.40 million. On average, sell-side analysts forecast that Genmab A/S Sponsored ADR will post 1.45 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Genmab A/S from a “hold” rating to a “buy” rating in a research note on Saturday, November 22nd. HC Wainwright reiterated a “buy” rating and issued a $39.00 price objective on shares of Genmab A/S in a research report on Wednesday. Johnson Rice restated a “buy” rating on shares of Genmab A/S in a research report on Monday, October 27th. Truist Financial restated a “buy” rating and issued a $48.00 target price (down from $49.00) on shares of Genmab A/S in a research note on Thursday, November 6th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Genmab A/S in a research note on Wednesday, October 8th. Six analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Genmab A/S has a consensus rating of “Moderate Buy” and a consensus price target of $39.25.

Genmab A/S News Summary

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: HC Wainwright reaffirmed its “Buy” rating and $39 price target on GMAB, implying roughly mid-teens upside from current levels — supportive of investor demand. H.C. Wainwright Reiterates Buy Rating on Genmab AS (GMAB)
• Positive Sentiment: HC Wainwright raised its FY2025 EPS projection to $2.00 (from $1.89), signaling higher expected full-year profitability that can support valuation. HC Wainwright / Marketbeat
• Neutral Sentiment: Genmab granted 32,806 restricted stock units and 34,307 warrants to employees. The award is standard compensation-related dilution but is very small relative to the company’s outstanding shares, so impact is likely minimal. Grant of Restricted Stock Units and Warrants to Employees in Genmab
• Neutral Sentiment: Reported short-interest data for January appear anomalous (showing 0 shares / NaN change) and are inconclusive — not a reliable signal of bearish pressure at this time.
• Negative Sentiment: HC Wainwright cut near-term quarterly EPS forecasts (Q1 → $0.27 from $0.34; Q2 → $0.49 from $0.58; Q3 → $0.47 from $0.59), which reduces near-term earnings expectations and could weigh on sentiment if investors focus on short-term performance. HC Wainwright / Marketbeat

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.